FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up - Medscape

The US Food and Drug Administration has approved semaglutide 2.4 mg (Wegovy), a once-weekly subcutaneous injection, for the additional indication of treating obesity in adolescents aged 12 years and older.

This is defined as those with an initial BMI at or above the 95th percentile for age and sex (based on CDC growth charts). Semaglutide must be administered along with lifestyle intervention of a reduced calorie meal plan and increased physical activity.

When Wegovy was approved for use in adults with obesity in June 2021, it was labeled a "game changer."

The new approval is based on the results of the STEP TEENS phase 3 trial of once-weekly 2.4 mg of semaglutide in adolescents 12- to <18 years old with obesity, the drug's manufacturer, Novo Nordisk, announced in a press release.

In STEP TEENS, reported at Obesity Week 2022 in November, and simultaneously published in the New England Journal of Medicine, adolescents with obesity treated with semaglutide for 68 weeks had a 16.1% reduction in BMI compared with a 0.6% increase in BMI in those receiving placebo. Both groups also received lifestyle intervention. Mean weight loss was 15.3 kg (33.7 lb) among teens on semaglutide, while those on placebo gained 2.4 kg (5.3 lb).

At the time, Claudia K. Fox, MD, MPH, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota Medical School — who was not involved with the research — told Medscape the results were "mind-blowing…we are getting close to bariatric surgery results" in these adolescent patients with obesity.

Semaglutide is a GLP-1 agonist, as is a related agent, also from Novo Nordisk, liraglutide (Saxenda), a daily subcutaneous injection, which was approved for use in adolescents aged 12 and older in December 2020. Wegovy is the first weekly subcutaneous injection approved for use in adolescents.

Other agents approved for obesity in those older than 12 in the US include the combination phentermine and topiramate extended-release capsules (Qsymia) in June 2022, and orlistat (Alli). Phentermine is approved for those aged 16 and older.  

For more diabetes and endocrinology news, follow us on Twitter and on Facebook .

FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up - Medscape

Comments

Post a Comment

Popular posts from this blog

Blue toe syndrome: Causes, treatment, outlook, and prevention - Medical News Today

Image
When one or more of a person's toes starts to look blue or purple, doctors call it blue toe syndrome. There are several triggers, most of which relate to the circulatory system. This article explains what blue toe syndrome is, what it feels like, its causes, and how doctors treat it. It will also explore the possible complications of blue toe syndrome and when to see a doctor. Share on Pinterest Blue toe syndrome can cause muscle pain in the legs, as well as severe pain in the foot. Doctors sometimes call it occlusive vasculopathy or trash foot. Blue toe syndrome is a form of acute digital ischemia. This means it occurs when the toes do not get enough blood. A person's blood carries oxygen from the lungs to every part of their body. Each cell needs oxygen to repair itself and multiply. The blood also brings cells all the nutrients they need and carries away waste products. Not getting enough blood damages cells and the tissues they make up. This can cause the tissue to change c
Read more

Effect of pharmacogenetic variations on praziquantel plasma ... - Nature.com

Image
Abstract School-based mass drug administration (MDA) of Praziquantel (PZQ) is the global intervention strategy for elimination of schistosomiasis. Genetic variations in drug metabolizing enzymes and transporter proteins influences drug exposure and treatment outcomes, but data on PZQ pharmacokinetics and safety outcomes are scarce. We investigated the effect of pharmacogenetics variations on PZQ plasma concentrations and safety outcomes among 462 Rwandan schoolchildren who received single dose PZQ and albendazole in MDA. Genotyping for common functional variant alleles CYP3A4*1B , CYP3A5 (*3, *6, *7), CYP2C19 (*2, *3, *17), CYP2C9 (*2, *3) and CYP2J2*7 were done. Plasma concentration of PZQ, cis -4-OH-PZQ and trans -4-OH-PZQ were measured using LC/MS/MS. Active safety monitoring was done on days 1, 2, and 7 post-MDA. CYP2C9 and CYP2C19 genotypes were significantly associated with PZQ plasma concentrations and its cis - and trans -4-OH-PZQ/PZQ metabolic ratios (MR). CYP2C9*2 and
Read more